BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2025 7:47:40 AM | Browse: 114 | Download: 804
 |
Received |
|
2025-05-20 07:13 |
|
Peer-Review Started |
|
2025-05-20 07:13 |
|
First Decision by Editorial Office Director |
|
2025-05-26 23:51 |
|
Return for Revision |
|
2025-05-26 23:51 |
|
Revised |
|
2025-05-30 01:07 |
|
Publication Fee Transferred |
|
2025-06-03 10:49 |
|
Second Decision by Editor |
|
2025-06-23 02:41 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-06-23 04:52 |
|
Articles in Press |
|
2025-06-23 04:52 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-04 06:11 |
|
Publish the Manuscript Online |
|
2025-07-11 07:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu and Zhen-Yu Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Scientific Research Program of FuRong Laboratory |
No. 2023SK2108 |
| Clinical Medical Research Center for Viral Hepatitis of Hunan Province |
No. 2023SK4009 |
| Hunan Provincial Natural Science Foundation |
No. 2023JJ60440 |
| Hunan Provincial Health Commission Research Program |
No. 202303088786 |
|
| Corresponding Author |
Zhen-Yu Xu, PhD, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, No. 139 People’s Middle Road, Changsha 410011, Hunan Province, China. xuzhenyu@csu.edu.cn |
| Key Words |
Tenofovir amibufenamide; Hepatitis B virus; Lipid profile; Lipoprotein; Cholesterol |
| Core Tip |
This 144-week dual-phase study investigated the long-term lipid and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B patients. Through a randomized, double-blind comparison with tenofovir disoproxil fumarate (TDF) followed by a TDF-to-TMF switch, the trial revealed comparable antiviral efficacy, improved renal and bone safety, and a moderate elevation in lipid levels with TMF that stabilized after switch therapy. These findings support TMF as a viable first-line and sequential therapy option in real-world chronic hepatitis B management. |
| Publish Date |
2025-07-11 07:47 |
| Citation |
Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i26.109285 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
